Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
RANBAXY IN PRICE-FIXING CASE
 


Ranbaxy among the five drugmakers facing criminal charges for price-fixing of antibiotics & warfarin

The Indian drug major Ranbaxy is among the five pharmaceutical companies facing criminal charges of conspiracy to defraud the British National Health Service, for fixing prices of generic penicillin-based antibiotics and and blood-clotting drug warfarin.

BY OUR PHARMA CORRESPONDENT
April 10, 2006

Apart from the British arm of Ranbaxy in India, other four drug companies are Kent Pharmaceuticals, Norton Healthcare (now a unit of Teva Pharmaceuticals), Generics U.K., and Goldshield Group. Nine executives were also accused of fixing prices and sharing market information.

The probe began in April 2002 after allegations that British generic drug providers had colluded to set prices from 1996 to 2000. Suppliers of generic penicillin-based antibiotics and warfarin, an anticoagulant, were the focus of the inquiry.

The criminal charges focus on conspiracy to defraud because price-fixing was not a criminal offense until 2002, when Britain passed a law making it illegal. Some of the companies facing charges have already paid more than £10 million (about $17 million) to settle charges with the Department of Health, without admitting any liability.

However, Ranbaxy said that it had not yet seen the allegations.Norton Healthcare said it believed that sales of warfarin and antibiotics during the time covered by the investigation were in compliance with existing laws. Goldshield said it and its executives had not acted in an unlawful or improper way. Generics, which is owned by Merck of Germany, and Kent Pharmaceuticals had no comment.

"This important case involving an allegation of dishonest price fixing by companies is likely to have a significant impact upon the business culture of this country," said Philip Lewis, an assistant director with the Serious Fraud Office, according to a press release.

The fraud agency is under pressure to make sure the investigation bears fruit. The unit is often referred to as the "Serious Farce Office" by the satirical weekly magazine Private Eye, in part because of a history of failing to win convictions. It could be in danger of losing some major investigations to a new organized crime agency begun this month that is modeled on the Federal Bureau of Investigation.



More related stories from Pharma


Healing prayers no cure for the ill, says study

Pulmonary hypertension drug PulmoLAR in human trial

Pharma markets in China, Korea, Mexico, Russia & Turkey gather pace

Pfizer’s anxiety drug Lyrica gets EU nod

Asymmetrical breasts: A presage to cancer?

Dream to eradicate polio still far off

GlaxoSmithKline loses fluticasone case

Able files recast plan with bankruptcy court

Ranbaxy in pact with Zenotech on cancer drugs

Lupin and Aspen to form JV on TB drugs

Blood cancer drug Ceflatonin gets orphan drug status

Bangladesh to set up API park; to export drugs worth Tk 8.50 cr to Burma

Wockhard Limited: A profile
Cipla Ltd company profile

 

 

 

Auto news for auto freaks! iDrive.in
DWS community! / Cricket blog

 

Latest Stories in Pharma

 

Drug price control may be re-imposed in India

Patent oppositions galore in India’s new IP era

Ranbaxy may move US Supreme Court on Lipitor patent

India -Preferred partner for biotech industry?

Five drugmakers facing criminal charges

Shire's Daytrana skin patch okayed for ADHD in kids

Anti-depressant use in pregnancy may lead to still-borns

Ovary removal before menopause could cause memory loss

New vaccine vows to expel cervical cancer

Linking cell phone use with brain cancer disputed

TGN1412 mishap

 

 

Latest Stories in Pharma

Pharma stories archived on 7 Jan 2007

Pharma stories archived on 14 Sep, 2005

 

 

 

Latest updates    Contact Us - Feedback    About Us